Our Medical Advisory Committee advises MPE and provides evidence-based recommendations to our team and members in support of advocacy initiatives. It is comprised of key opinion leaders representing myeloma and AL amyloidosis specialities, as well as MPE’s member countries. They update us on myeloma and AL amyloidosis disease, diagnostics and treatments.
The activities of the Medical Advisory Committee are defined by the patient community’s current unmet needs and concerns, and are organised around clinical practice, research, technical and medical questions. Its members give talks, webinars and interviews at scientific conferences, review communication documents, answer clinical questions, disseminate and participate in surveys, collaborate on research projects and join discussion groups on selected topics. The Medical Advisory Committee meets once a year to discuss the past year’s activities, future projects and current needs and challenges.